Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jan 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-01-20

Reporting Person: Hernandez Alexandra (Sr Director Finance/Controller)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$0.6919	2030-03-17	Common Shares (45200)		Direct
Employee Stock Option (Right to Buy)	$0.9000	2029-09-01	Common Shares (100000)		Direct

Footnotes

F1: One quarter of the options will vest on March 17, 2021 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment

F2: One quarter of the options vested on September 1, 2020 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment